This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine